Liver cancer and transplant study for MASLD patients
Part of Cancer, Digestive system clinical trials.
This study looks at factors that predict liver cancer and the need for a liver transplant in people with a liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease). The goal is to better understand the disease and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of MASLD (a liver condition linked to metabolism).
- You are 18 years old or older.
- You need a liver biopsy as part of your regular medical care.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a more detailed way to examine the liver in people with fatty liver disease who also have other health risks. The doctors want to see if this extra testing helps decide whether you need treatment.
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
This study uses routine blood tests to find people with advanced liver scarring caused by a condition called MASLD. If you are between 50 and 75, have certain metabolic risks, and get blood work from your primary care doctor at select centers, you may be eligible.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study aims to build a tool to predict how MASLD-related cirrhosis (fatty liver disease leading to liver scarring) will progress. It may help doctors and patients better understand the outlook and plan care.
This trial tests if a medicine called Mazdutide can help overweight living liver donors who have a fatty liver condition (MASLD) lose weight and improve their liver health before donating part of their liver. It aims to make the donation safer and more successful.
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.